5318 J ournal of Medicinal Chemistry, 1998, Vol. 41, No. 26
Rosowsky et al.
Su p p or tin g In for m a tion Ava ila ble: IR and 1H NMR
spectral data for compounds 21, 23-25, 31, 37, and 38 (2
pages). Ordering information is given on any current masthead
page.
(12) J ohnson, J . M.; Meiering, E. M.; Wright, J . E.; Pardo, J .;
Rosowsky, A.; Wagner, G. NMR solution structure of the
antitumor compound PT523 and NADPH in the ternary complex
with human dihydrofolate reductase. Biochemistry 1997, 36,
4399-4411.
(13) Cody, V.; Galitsky, N.; Luft, J . R.; Pangborn, W.; Rosowsky, A.;
Blakley, R. L. Comparison of two independent crystal structures
of human dihydrofolate reductase ternary complexes with
reduced nicotinamide adenine dinucleotide phosphate and the
very tight-binding inhibitor PT523. Biochemistry 1997, 36,
13897-13903.
Refer en ces
(1) Rosowsky, A. Development of nonpolyglutamatable DHFR in-
hibitors. In Antifolate Drugs: Basic Research and Clinical
Practice; J ackman, A. L., Ed.; Humana Press: Totowa, NJ ; in
press.
(14) (a) Klohs, W. D.; Steinkampf, R. W.; Besserer, J . A.; Fry, D. A.
Cross resistance of pleiotropically drug resistant P388 leukemia
cells to the lipophilic antifolates trimetrexate and BW301U.
Cancer Lett. 1986, 31, 253-260. (b) Ramu, N.; Ramu, A.; Cole,
D. E.; Balis, F. M.; Poplack, D. G.; Pollard, H. B. Mechanism of
acquired resistance to methotrexate in P388 cells and in their
doxorubicin-resistant subline. Israel J . Med. Sci. 1988, 24, 477-
482. (c) Assaraf, Y. G.; Molina, A.; Schimke, R. T. Cross-
resistance to the lipid-soluble antifolate trimetrexate in human
carcinoma cells with the multidrug-resistant phenotype. J . Natl.
Cancer Inst. 1989, 81, 290-294.
(15) (a) Rosowsky, A.; Bader, H.; Wright, J . E.; Keyomarsi, K.;
Matherly, L. H. Synthesis and biological activity of Nω-hemi-
phthaloy-R,ω-diaminoalkanoic acid analogues of aminopterin
and 3′,5′-dichloroaminopterin. J . Med. Chem. 1994, 37, 2167-
2174. (b) Rosowsky, A.; Vaidya, C. M.; Bader, H.; Wright, J . E.;
Teicher, B. A. Analogues of NR-(4-amino-4-deoxy)-Nδ-hemi-
phthaloyl-L-ornithine (PT523) modified in the side chain: syn-
thesis and biological evaluation. J . Med. Chem. 1997, 40, 286-
299.
(16) (a) Allegra, C. J .; Drake, J . C.; J olivet, J .; Chabner, B. A.
Inhibition of phosphoribosyl-aminoimidazolecarboxamide trans-
formylase by methotrexate and dihydrofolic acid polyglutamates.
Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 4881-1885. (b) Allegra,
C. J .; Chabner, B. A.; Drake, J . C.; Lutz, R.; Rodbard, D.; J olivet,
J . Enhanced inhibition of thymidylate synthase by methotrexate
polyglutamates. J . Biol. Chem. 1985, 260, 9720-9726.
(17) Rosowsky, A.; Forsch, R. A.; Bader, H.; Freisheim, J . H.
Synthesis and in vitro biological activity of new deaza analogues
of folic acid, aminopterin, and methotrexate with an L-ornithine
side chain. J . Med. Chem. 1991, 34, 1447-1454.
(18) Piper, J . E.; McCaleb, G. S.; Montgomery, J . A.; Kisliuk, R. L.;
Gaumont, Y.; Sirotnak, F. M. Syntheses and antifolate activity
of 5-methyl-5-deaza analogues of aminopterin, methotrexate,
folic acid, and N10-methylfolic acid. J . Med. Chem. 1986, 29,
1080-1087.
(2) (a) Matsuoka, H.; Ohi, N.; Mihara, M.; Suzuki, H.; Miyamoto,
K.; Maruyama, N.; Tsuji, K.; Kato, N.; Akimoto, T.; Takeda, Y.;
Yano, K.; Kuroki, T. Antirheumatic agents: Novel methotrexate
derivatives bearing a benzoxazine moiety. J . Med. Chem. 1997,
40, 105-111. (b) Mihara, M.; Takagi, N.; Urakawa, K.; Moriya,
Y.; Takeda, Y. Preventive effect of a novel antifolate, MX-68, in
murine systemic lupus erythematosis (SLE). Int. J . Immuno-
pharmacol. 1997, 19, 67-74.
(3) Kokuryo, Y.; Kawata, K.; Nakatani, T.; Kugimiya, A.; Tamura,
Y.; Kawada, K.; Matsumoto, M.; Suzuki, R.; Kuwabara, K.; Hori,
Y.; Ohtani, M. Synthesis and evaluation of novel fluorinated
methotrexate derivatives for application to rheumatoid arthritis
treatment. J . Med. Chem. 1997, 40, 3280-3291.
(4) Rosowsky, A.; Forsch, R.; Uren, J .; Wick, M.; Kumar, A. A.;
Freisheim, J . H. Methotrexate analogues. 20. Replacement of
glutamate by longer-chain amino diacids: Effects on dihydro-
folate reductase inhibition, cytotoxicity, and in vivo antitumor
activity. J . Med. Chem. 1983, 26, 1719-1724.
(5) (a) Li, E.-W.; Lin, J . T.; Tong, W. P.; Trippett, T. M.; Brennan,
M. F.; Bertino, J . R. Mechanisms of natural resistance to
antifolates in human soft tissue sarcomas. Cancer Res. 1992,
52, 1434-1438. (b) Li, W.-W.; Lin, J . T.; Schweitzer, B. I.; Tong,
W. P.; Niedzwicki, D.; Bertino, J . R. Intrinsic resistance to
methotrexate in human soft tissue sarcoma cell lines. Cancer
Res. 1992, 52, 3908-3913.
(6) (a) Pizzorno, G.; Chang, Y. M.; McGuire, J . J .; Bertino, J . R.
Inherent resistance of human squamous carcinoma cell lines to
methotrexate as a result of decreased polyglutamylation of this
drug. Cancer Res. 1989, 49, 5275-5280. (b) van Der Laan, B. F.
A. M.; J ansen, G.; Kathmann, G. A. M.; Westerhof, G. R.;
Schornagel, J . H.; Hordijk, G. J . In vitro activity of novel
antifolates against human squamous carcinoma cell lines of the
head and neck with inherent resistance to methotrexate. Int. J .
Cancer 1992, 51, 909-914.
(7) Barakat, R. R.; Li, W.-W.; Lovelace, C.; Bertino, J . R. Intrinsic
resistance of cervical squamous cell carcinoma cell lines to
methotrexate (MTX) as a result of decreased accumulation of
intracellular MTX polyglutamates. Gynecol. Oncol. 1993, 51, 54-
60.
(8) (a) Whitehead, V. M.; Rosenblatt, D. S.; Vuchich, M.-J .; Shuster,
J . J .; Witte, A.; Beaulieu, D. Accumulation of methotrexate and
methotrexate polyglutamates in lymphoblasts at diagnosis of
childhood acute lymphoblastic leukemia; A pilot prognostic factor
analysis. Blood 1990, 76, 44-49. (b) Lin, J . T.; Tong, W. P.;
Trippett, T. M.; Nidzwiecki, D.; Tao, Y.; Tan, C.; Steinherz, P.;
Schweitzer, I.; Bertino, J . R. Basis for natural resistance to
methotrexate in human acute nonlymphocytic leukemia. Leu-
kemia Res. 1991, 15, 1191-1196. (c) Barredo, J . C.; Synold, T.
W.; Laver, J .; Relling, M. V.; Pui, C.-C.; Priest, D. G.; Evans, W.
E. Differences in constitutive and post-methotrexate folylpoly-
glutamate synthetase activity in B-lineage and T-lineage leu-
kemia. Blood 1994, 84, 564-569. (d) Galpin, A. M.; Schuetz, J .
D.; Masson, E.; Yanishevski, Y.; Synold, T. E.; Barredo, J . C.;
Pui, C.-H.; Relling, M. V.; Evans, W. E. Differences in folylpoly-
glutamate synthetase and dihydrofolate reductase expression in
human B-lineage versus T-lineage leukemic lymphoblasts: mech-
anisms for lineage differences in methotrexate polyglutamation
and cytotoxicity. Mol. Pharmacol. 1997, 52, 155-163.
(9) (a) Rosowsky, A.; Bader, H.; Cucchi, C. A.; Moran, R. G.; Kohler,
W.; Freisheim, J . H. Methotrexate analogues. 33. Nδ-Acyl-NR-
(4-amino-4-deoxypteroyl)-L-ornithine derivatives: synthesis and
in vitro antitumor activity. J . Med. Chem. 1988, 31, 1322-1337.
(b) Rosowsky, A.; Bader, H.; Forsch, R. A. Synthesis of the
folylpolyglutamate synthetase inhibitor NR-pteroyl-L-ornithine
and its Nδ-benzoyl and Nδ-hemiphthaloyl derivatives, and an
improved synthesis of NR-(4-amino-4-deoxypteroyl)-Nδ-hemiph-
thaloyl-L-ornithine. Pteridines 1989, 1, 91-98.
(19) An alternative route to 18 and 19 would be to condense
4-aminobenzoic acid with 2,4-diamino-6-(bromomethyl)pyrido-
[2,3-d]pyrimidines; see: Piper, J . R.; Malik, N. D.; Rhee, M. S.;
Galivan, J .; Sirotnak, F. M. Synthesis and antifolate evaluation
of the 10-propargyl derivatives of 5-deazafolic acid, 5-deazaami-
nopterin, and 5-methyl-5-deazaaminopterin. J . Med. Chem.
1992, 35, 332-337.
(20) Srinivasan, A.; Broom, A. Pyridopyrimidines. 12. Synthesis of
8-deaza analogues of aminopterin and folic acid. J . Org. Chem.
1981, 46, 1777-1781.
(21) An improved method of preparation of 26‚HBr was subsequently
developed; see: Rosowsky, A.; Forsch, R. A.; Queener, S. F. 2,4-
Diaminopyrido[3,2-d]pyrimidine inhibitors of dihydrofolate re-
ductase from Pneumocystis carinii and Toxoplasma gondii. J .
Med. Chem. 1995, 38, 2615-2620.
(22) Davoll, J .; J ohnson, A. M. Quinazoline analogues of folic acid.
J . Chem. Soc. 1970, 997.
(23) Prendergast, N. J .; Delcamp, T. J .; Smith, P. L.; Freisheim, J .
H. Expression and site-directed mutagenesis of human dihy-
drofolate reductase. Biochemistry 1988, 27, 3664- 3671.
(24) Appleman, J . R.; Prendergast, N.; Delcamp, T. J .; Freisheim, J .
H.; Blakley, R. L. Kinetics of the formation and isomerization
of methotrexate complexes of recombinant human dihydrofolate
reductase. J . Biol. Chem. 1988, 263, 10304-10313.
(25) Henderson, P. J . F. A linear equation that describes the steady-
state kinetics of enzymes and subcellular particles interacting
with tightly bound inhibitors. Biochem. J . 1972, 127, 321-333.
(26) J ackson, R. C.; Hart, L. I.; Harrap, K. R. Intrinsic resistance to
methotrexate of cultured mammalian cells in relation to the
inhibition kinetics of their dihydrofolate reductases. Cancer Res.
1976, 36, 1991-1997.
(27) Sirotnak, F. M.; Schmid, F. A.; Otter, G. M.; Piper, J . R.;
Montgomery, J . A. Structural design, biochemical properties, and
evidence for improved therapeutic activity of 5-alkyl derivatives
of 5-deazaminopterin and 5-deazamethotrexate compared to
methotrexate in murine tumor models. Cancer Res. 1988, 48,
5686-5691.
(10) Westerhof, G. R.; Schornagel, J . H.; Kathmann, I.; J ackman, A.
L.; Rosowsky, A.; Forsch, R. A.; Hynes, J . B.; Boyle, F. T.; Peters,
G. J .; Pinedo, H. M.; J ansen, G. Carrier- and receptor-mediated
transport of folate antagonists targeting folate-dependent en-
zymes: correlates of molecular structure and biological activity.
Mol. Pharmacol. 1995, 48, 459-471.
(11) Rhee, M. S.; Galivan, J .; Wright, J . E.; Rosowsky, A. Biochemical
studies on PT523, a potent nonpolyglutamatable antifolate, in
cultured cells. Mol. Pharmacol. 1994, 45, 783-791.